CareDx, Inc rose 22.2% on Friday, October 30, 2026, on 3,552,531 shares, 2.7 times its average daily volume. Headlines around the move:
CareDx, Inc (CDNA:NASDAQ) closed at $87.41 on October 30, 2026, up 22.22% on the day. The stock trades 3.8% below its 52-week high of $90.87 and 512.5% above its 52-week low of $14.27. Over the past year, it gained 482.7%. CareDx, Inc is part of the Health Care sector (Medical Specialities).
In 252 trading sessions since October 30, 2025, CDNA closed higher on 137 days (54%). Its best day was July 16, 2026 (+35.60%) and its worst was November 6, 2025 (-9.20%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 5 times.
CareDx, Inc., a molecular diagnostics company, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in the United States and internationally. The company's commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. It is also developing AlloSure, a next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. The company markets its AlloMap solution to healthcare providers through its direct sales force that targets transplant centers and their physicians, coordinators, and nurse practitioners. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
Find more stocks like CDNA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.